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ommendations to decrease noncompliance include: 1) replacing
ﬁll-ahead pharmacy dispensing with automated queuing systems;
2) instituting reminder phone calls for more beneﬁciaries 
who use the telephone reﬁll system; 3) implementing efforts to
increase compliance among active duty military personnel; and
4) modifying the way military providers receive noncompliance
reports.
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OBJECTIVES: Concentrations of some drugs appear to have
inappropriate indications or suboptimal timing, particularly in
the inpatient setting. It is important to know the concentration
of the drug taken because each drug has a minimum and
maximum level for best performance. Several studies have doc-
umented that the appropriate use of pharmacokinetic drug 
monitoring, particularly in conjunction with a clinical pharma-
cokinetic monitoring (CPM) service, is both efﬁcient and cost-
effective. The aim of this study is to evaluate the effectiveness of
a computerized CPM system which was implemented in a
medical center. Indicators of medication outcome were collected
prior to and after the CPM system was introduced. METHODS:
The drug Digoxin is representative and being evaluated in this
study. Several objective indicators were used to estimate cost-
effectiveness of this CPM. These included day interval of abnor-
mal serum concentration, costs of laboratory blood test, length
of stay and drug cost. RESULTS: After introducing the CPM
system, day intervals of abnormality in serum concentration are
signiﬁcantly reduced by 3.53 days/patient. Average length of stay
signiﬁcantly decreases after the CPM, from 32.13 to 27.92 days
in average. The cost of laboratory blood test can be saved is
US$33.27/patient. In addition, the cost of toxicity therapy was
found signiﬁcantly reduced by US$9.68/patient (US$23.76/
patient vs. US$14.09/patient; p < 0.05), due to reducing the 
use of Lidocaine, Phenytoin and anti-diarrhea drugs. Similarly, 
signiﬁcant reduction was found as US$9.42/patient (from
US$22.82/patient to US$13.41/patient; p < 0.05) for the cost of
combined therapy in the over-optimal group. CONCLUSION:
This study provides the evidence for the effectiveness of the com-
puterized CPM system by several indicators. The implementa-
tion of the CPM system is meaningful in pharmaceutical care
that can improve quality of patient care as well as enhance
patient safety.
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OBJECTIVE: To measure the effects of a participant-centric
mailing focusing on out-of-pocket costs opportunities driven by
medication alternatives and delivery channel choices in a phar-
macy beneﬁts system. METHODS: Plan-participants from a
large employer that participated in the mailing program (n =
21,055) were compared to a control group of plan-participants
selected from an employer that did not participate in the
program (n = 21,055), matched on gender and Health Risk Index
score. Pharmacy claims data for all continuously eligible
study/control plan-participants age 18 and older were retro-
spectively examined over a baseline period from January 14 to
April 13, 2004 (pre-mailing), and a follow-up period from April
14 to November 14, 2004 (post-mailing). Two separate logistic
regression models were constructed to assess whether participa-
tion in the program was associated with an increase in plan-
participant rate of 1) mail-service pharmacy utilization (i.e.
increase: yes/no), and 2) formulary compliance, while control-
ling for plan-participant baseline: demographics, utilization and
costs. RESULTS: The logistic regression model for increase in
mail-service pharmacy utilization showed that plan-participants
who received the mailing were signiﬁcantly more likely to
increase mail utilization in comparison to control plan-
participants (adjusted odds ratio (OR) = 1.30; 95 percent conﬁ-
dence interval (CI) = 1.17 - 1.43). Plan-participants receiving the
mailing also had a signiﬁcantly higher likelihood of increasing
formulary compliance compared to the control group (adjusted
OR = 1.30; 95% CI = 1.19 - 1.42) from the model for formu-
lary compliance. CONCLUSIONS: This preliminary analysis
showed that plan-participants receiving the program mailing
were more likely to increase formulary compliance and mail-
service prescription utilization. Final program outcome analyses
are to be completed employing a lengthier follow-up period,
larger sample sizes and additional control factors.
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OBJECTIVES: Advantage90TM is Walgreens Health Initiatives’
90-day retail program allowing patients to obtain 90-day sup-
plies of maintenance medications from a network of retail phar-
macies. This study evaluated the changes in prescription drug
utilization and costs after the introduction of this program.
METHODS: Using a pre-post (8 months from the enrollment
date) cohort study design, prescription records were obtained
from Walgreens Health Initiatives’ pharmacy claims database.
Clients enrolled in Advantage90TM during January 1, 2004 and
May 1, 2004 were included. Clients without 3-tier formulary
design and rebate-eligibility were excluded. For the purpose of
this study, specialty drugs were excluded. Number of prescrip-
tion dispensed, costs per prescription (normalized to 90-day
supply) and generic percentages in Advantage90TM, mail service
and 30-day retail were analyzed and compared. RESULTS: Sev-
enteen clients with a total of 236,950 eligible lives met the inclu-
sion criteria. A total of 1,618,240 prescriptions, 802,345 in the
pre period (5% mail and 95% 30-day retail) and 815,895 in the
post period (14% Advantage90TM, 4% mail and 82% 30-day
retail) were included. The average total cost per prescription was
signiﬁcantly lower in Advantage90TM than in mail service and
30-day retail ($129.39 vs. $191.15 vs. $205.09, p < 0.0001).
Health plans paid signiﬁcantly less for per prescription in 
Advantage90TM than in mail service and 30-day retail ($100.08
vs. $159.48 vs. 155.01, p < 0.0001). Per prescription co-pay-
ments from patients were $29.21 in Advantage90TM, $31.50 in
mail service and $49.55 in 30-day retail. The generic utilization
rate was higher in Advantage90TM than in mail service and 
30-day retail (60.1% vs. 35.8% vs. 42.8%, p < 0.0001). CON-
CLUSIONS: Availability of a 90-day retail program such as
Advantage90TM can decrease total, health plan and member costs
while increasing generic utilization rate. A 90-day retail program
should be considered as an option to lowering prescription drug
costs.
